MediciNova, Inc. (MNOV )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol MNOV
- Company MediciNova, Inc.
- Price $3.45
- Changes Percentage 36.9
- Change 0.93
- Day Low $2.83
- Day High $3.9
- Year High $1.96
- Year Low $1.17
- Market Cap $68,417,532
- Price Avg 50 EMA (D) $1.34
- Price Avg 200 EMA (D) $1.43
- Exchange NASDAQ
- Volume 26,802
- Average Volume 48,925
- Open $2.84
- Previous Close $2.52
- EPS -0.21
- PE -6.62
- Earnings Announcement 2026-11-12 12:00:00
- Shares Outstanding $49,221,246
Company brief: MEDICINOVA, INC. (MNOV )
- Healthcare
- Biotechnology
- Dr. Yuichi Iwaki M.D., Ph.D.
- https://www.medicinova.com
- US
- N/A
- 12-08-2006
- US58468P2065
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.